When was Context Therapeutics founded?

Context Therapeutics was founded in 2015 and raised its 1st funding round 6 years after it was founded.

Where is Context Therapeutics located?

Context Therapeutics is headquartered in Philadelphia, United States.

Who is the current CEO of Context Therapeutics?

Martin Lehr of Context Therapeutics.

How many employees does Context Therapeutics have?

As of Jul 31, 2026, the latest employee count at Context Therapeutics is 29.

Is Context Therapeutics a funded company?

Context Therapeutics is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Dec 01, 2021.

When was the latest funding round of Context Therapeutics?

Context Therapeutics' latest funding was a $***** Post IPO round on May 06, 2024, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.95B in funding in 2026 to date.

Where does Context Therapeutics rank among its competitors?

Context Therapeutics ranks 182nd amongst 3344 active competitors, of which 1124 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Context Therapeutics?

Context Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Context Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developing T cell engaging bispecific antibody therapies for solid tumors. The company is dedicated to advancing the next generation of T cell engaging (TCE) bispecific antibody therapies to treat solid tumors. It is building an innovative portfolio of clinical-stage TCE bispecific antibody therapeutics. The pipeline includes product candidates targeting Claudin 6, Mesothelin, and Nectin-4. The company's purpose is driven by a passion for helping patients with cancer and a belief that better treatments are possible. The focus is on innovation in the field of cancer therapeutics, specifically through the development of bispecific antibody technology. The company values inclusion, transparency, and accountability in its operations.

Website: www.contexttherapeutics.com/
Social
Email ID: *****@contexttherapeutics.com

Key Metrics

Founded Year

2015

Location

Philadelphia, United States

Stage

Public

Latest Funding Round

Post IPO, May 06, 2024, $*****

Investors

Nextech Invest & 1 more

Ranked

182^nd among 3344 active competitors

Employee Count

29 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2996 more

Exit Details

Public

View Context Therapeutics' full profile

Context Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CONTEXT THERAPEUTICS INC. CIN: 1842952 , United States, Active	Apr 19, 2021	-	7 (As on Mar 31, 2022)	-
Context Therapeutics Inc CIN: 86-3738787 , United States, Active	Dec 31, 2014	-	-	-

Context Therapeutics got listed on Oct 20, 2021.

Click here to take a look at Context Therapeutics's IPO in detail

Context Therapeutics has raised funding over 2 rounds. Its first funding round was on Dec 01, 2021. Context Therapeutics has 2 institutional investors.

Here is the list of recent funding rounds of Context Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 06, 2024	3383617	Post IPO	5901243	1912346	5900461	2940787
Dec 01, 2021	4249629	Post IPO	1313238	5187891	7495715	7649939

Access funding benchmarks and valuations. Sign up today!

View details of Context Therapeutics's funding rounds and investors

The founders of Context Therapeutics are Martin Lehr and Felix Kim.

Here are the details of Context Therapeutics' key team members:

Martin Lehr: Co-Founder & CEO of Context Therapeutics.
Contact Info: 1 email address
Felix Kim: Co-Founder of Context Therapeutics.

View details of Context Therapeutics's Founder profiles and Board Members

Context Therapeutics' employee count trend

Context Therapeutics has 29 employees as of Jul 26. Here is Context Therapeutics's employee count trend over the years:

Employee count trend for Context Therapeutics

Uncover Context Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Context Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Context Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
182nd	Context Therapeutics 2015, Philadelphia (United States), Public	Developing T cell engaging bispecific antibody therapies for solid tumors	-	Nextech Invest, Osage University Partners	59/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Context Therapeutics's competitors? Click here to see the top ones

Context Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Context Therapeutics's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Context Therapeutics

Media has covered Context Therapeutics for a total of 8 events in the last 1 year, 4 of them have been about company updates and 1 about people movement.